Urolithin A Affects Muscle and Mitochondria in Older Adults

No serious side effects were reported.


Skeletal MuscleSkeletal Muscle

A study published in the Journal of the American Medical Association has examined the dosage and safety of a urolithin A supplement [1]. This study also examined urolithin A‘s effect on muscle endurance and specific health biomarkers.

A randomized, controlled clinical trialย 

This study is a follow-up to prior work done by the Amazentis company, with collaborators at the University of Washington Medical center and the Red Hutchinson Cancer Research center in Seattle [2]. This placebo-controlled, double-blinded study examined 50 women and 16 men ranging in age from 65 to 90. All of the participants identified as White, and all of them could perform daily activities without assistance.

Participants took four gel caps, totaling 1000 milligrams of urolithin A (Mitopureยฎ), in the morning on an empty stomach with 1 cup of water between March 2018 to July 2020. 15 individuals in the placebo group and 16 in the urolithin A group reported adverse events, but none were medically serious.

Improvements in function

120 days into this study, the placebo and urolithin A groups walked the same distance on a flat and hard surface in six minutes; however, both groups had significantly improved in this regard during that time. At month two, the urolithin A group enjoyed significant improvements in hand and leg skeletal muscles compared to placebo, and this improvement in the urolithin A group was further increased at month four.

Biomarker improvements

The researchers investigated whether taking urolithin A improved mitochondrial capacity in aged skeletal muscle. They did this by measuring maximal ATP production via magnetic resonance spectroscopy (MRS) and by examining the recovery rate of phosphocreatine. From baseline to 4 months, there was no significant difference in the maximal ATP production of skeletal muscles in the hand and leg.

In the urolithin A group, higher levels of urolithin A and its conjugate, urolithin A glucuronide, were detected 4 months after supplementation began. At two and four months, the urolithin A group also had significant reductions in several acylcarnitines and ceramides, which, in this study, represented improved mitochondrial function and decreased inflammation, respectively. Inflammation was directly examined by measuring the ratio of plasma levels of C-reactive protein from the start of the study to 4 months. The urolithin A group had significant reductions in plasma C-reactive protein during this time, but the placebo group did not.

There were no other significant differences between the placebo and urolithin A groups regarding blood chemistry parameters, vital signs, urinalysis, and hematology.


This study was limited in several ways. Daily physical activity was not monitored in this study, the participants were demographically homogenous, and the 6-minute walking distance did not differ between the two groups. The researchers suspect that this may be due to the study motivating some individuals to exercise. They suggest that future studies should have longer intervention times than 6 months, track daily physical activity, and select participants with reduced physical performance.

This study was funded by Amazentis, and the authors disclosed many conflicts of interest. Nevertheless, these results still provide pioneering insight on urolithin A supplement tolerability, and the results of this study suggest that it may be a promising approach to combat age-associated muscle decline. More research studies with larger sample sizes and a wider variety of participants are needed to confirm these results.


This article is only a very brief summary. It is not intended as an exhaustive guide and is based on the interpretation of research data, which is speculative by nature. This article is not a substitute for consulting your physician about which supplements may or may not be right for you. We do not endorse supplement use or any product or supplement vendor, and all discussion here is for scientific interest.

We would like to ask you a small favor. We are a non-profit foundation, and unlike some other organizations, we have no shareholders and no products to sell you. We are committed to responsible journalism, free from commercial or political influence, that allows you to make informed decisions about your future health.

All our news and educational content is free for everyone to read, but it does mean that we rely on the help of people like you. Every contribution, no matter if itโ€™s big or small, supports independent journalism and sustains our future. You can support us by making a donation or in other ways at no cost to you.

Developing a Treatment for Arthritis from Stem Cell Signals

Resarchers publishing in Aging have found that extracellular vesicles (EVs) derived from human umbilical cord mesenchymal stem cells (MSCs) reduce...

Creating a Noise Clock to Measure Biological Age

Publishing in Aging, the Conboy research lab has outlined the problems with existing machine learning-based clocks and created a new...

EARD2023: Using NFTs to Support Video Gaming for Good

In this talk, Lifespan.io President Keith Comito describes use cases for "Proof of Philanthropy" (PoP) dynamic NFTs - a new...

Senolytics as a Potential Back Pain Treatment

In a recent paper, researchers from McGill University in Canada have investigated how a combination of two senolytics, RG-7112 and...


[1] Liu, S., D’Amico, D., Shankland, E., Bhayana, S., Garcia, J. M., Aebischer, P., Rinsch, C., Singh, A., & Marcinek, D. J. (2022). Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial. JAMA network open, 5(1), e2144279. https://doi.org/10.1001/jamanetworkopen.2021.44279

[2] Singh, Anurag, Dโ€™Amico, D., Andreux, P. A., Dunngalvin, G., Kern, T., Blanco-Bose, W., โ€ฆ Rinsch, C. (2021). Direct supplementation with Urolithin A overcomes limitations of dietary exposure and gut microbiome variability in healthy adults to achieve consistent levels across the population. European Journal of Clinical Nutrition. https://doi.org/10.1038/s41430-021-00950-1

About the author


Tovah has been a Registered Dietitian Nutritionist (RDN) for the past 11 years in clinical, research, teaching, community, and industry roles. Her dissertation work was focused on nutritional and behavioral neuroscience approaches for chronic disease prevention. She was a writer for Lifespan.io from 2021-22 and is still an active volunteer with the org.
No Comments
Write a comment:


Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.